Market Overview

Benzinga's Top Initiations

Related ACAD
Benzinga's Volume Movers
ACADIA Pharmaceuticals Announces Stephen Davis As Executive VP, CFO And Chief Business Officer

Analysts at Deutsche Bank initiated coverage on shares of Sarepta Therapeutics (NASDAQ: SRPT) with a “buy” rating. The target price range for Sarepta Therapeutics is set to $45. Sarepta Therapeutics' shares closed at $33.03 yesterday.

Jefferies initiated coverage on shares of ACADIA Pharmaceuticals (NASDAQ: ACAD) with a “buy” rating. The target price for ACADIA Pharmaceuticals is set to $13. ACADIA Pharmaceuticals' stock closed at $6.18 yesterday.

Topeka Capital initiated coverage on shares of Schnitzer Steel Industries (NASDAQ: SCHN) with a “hold” rating. The target price for Schnitzer Steel Industries is set to $27. Schnitzer Steel Industries' shares closed at $28.60 yesterday.

Analysts at Bank of America initiated coverage on shares of Pluristem Therapeutics (NASDAQ: PSTI) with a “hold” rating. The target price for Pluristem Therapeutics is set to $3.50. Pluristem Therapeutics' shares closed at $3.17 yesterday.

Latest Ratings for SRPT

DateFirmActionFromTo
Jul 2014WBB SecuritesUpgradesSpeculative BuyBuy
May 2014Roth CapitalInitiates Coverage onBuy
Apr 2014CitigroupUpgradesSellNeutral

View More Analyst Ratings for SRPT
View the Latest Analyst Ratings

Posted-In: Top InitiationsInitiation Analyst Ratings

 

Related Articles (ACAD + PSTI)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters